ユーザーIDをお忘れですか? or パスワードをお忘れですか?

メニュー 戻る Poster-Presentations-Details

P09: Age Did Not Impact Participants’ Ease of Use for Reporting Their SARS-CoV-2 Symptoms in an Electronic Diary: Obvio-19 Results

Poster Presenter

      Susan M Dallabrida

      • CEO
      • SPRIM and Obviohealth
        United States


Key to understanding how to accurately track and monitor the appearance of COVID-19 symptoms among participants with SARS-CoV-2 may be whether age affects participant’s ability or willingness to complete an electronic symptom diary and provide information about their health/disease status.


Participants in a COVID-19 registrational study used the Obvio-19 app on their personal smartphones to report their possible SARS-CoV-2 symptoms and disease status daily.


In this prospective observational study (n=804, 6% SARS-CoV-2 positive), a subset (n=76) of all participants provided feedback about app usability and SARS-CoV-2 symptoms reporting. Participants’ were 23 to 74 years old (mean 48 years; median 47 years). Participants were grouped as “younger” (23 to 49 years, n=42) or “older” (50 to 74 years, n=34). Use of the app to participate in this study was not impacted by age: overall ease of use of the app itself averaged 4.69 + 0.68 in the younger group versus 4.88 + 0.37 in the older group (p =0.13) on a 5-point scale (5 rated as “very easy”). Similarly, in an age independent manner, participants noted that it was also easy to manage reporting on their SARS-CoV-2 symptoms and health status, averaging 4.95 + 0.31 in the younger group versus 4.79 + 0.64 in the older group (p =0.16) on a 5-point scale (5 rated as “easily manageable”). Age did not impact the time to completion as 96% of both groups reported that it required less than 2 minutes to complete their study activities (p=0.13).


Age was irrelevant to participants’ ability or willingness to report on their disease related symptoms and health status daily. Thus, electronic capture of SARS-CoV-2 symptoms data is effective and feasible across age groups and can be used in clinical trials and healthcare settings to collect near real time data from participants with COVID-19.